Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 2,208 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blinded (placebo) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects

NCT01409122
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
15 mg sodium nitrite inhalation solution, 90 mg sodium nitrite inhalation solution, 45 mg sodium nitrite inhalation solution, 120 mg sodium nitrite inhalation solution, 25% MTD sodium nitrite inhalation solution
Drug
Lead sponsor
Aires Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 56 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2012 · Synced Oct 16, 2026, 10:45 PM EDT
Active, not recruiting Phase 3 Interventional

Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

NCT06846541
View directory record Official record
Conditions
Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis, Severe Psoriasis
Interventions
Open-Label Envudeucitinib, Blinded Envudeucitinib, Placebo
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years and older
Enrollment
1,680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
92
States / cities
Birmingham, Alabama • Chandler, Arizona • Pheonix, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 16, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.

NCT01352845
View directory record Official record
Conditions
Healthy
Interventions
rLP2086, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 25 Years
Enrollment
3,301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
35
States / cities
Mobile, Alabama • Mesa, Arizona • Tempe, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 16, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 16, 2026, 10:45 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Use of an Oral Beta-2 Agonist in Persons With Spinal Cord Injury

NCT00755079
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
extended release beta-2 adrenergic agonist, placebo
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 16, 2026, 10:45 PM EDT
Completed Phase 1 Interventional

Safety Study of LLF580 in Obese Volunteers

NCT03466203
View directory record Official record
Conditions
Obesity
Interventions
LLF580, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Jacksonville, Florida • Miami, Florida • Overland Park, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 16, 2026, 10:45 PM EDT
Recruiting Phase 3 Interventional

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

NCT07227246
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Recombinant Factor VIIa, Biological/Vaccine: Placebo
Biological
Lead sponsor
Joseph Broderick, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
49
States / cities
Birmingham, Alabama • Baldwin Park, California • Burlingame, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 16, 2026, 10:45 PM EDT
Terminated Phase 2 Interventional Results available

A Study of CC-99677 in Participants With Active Ankylosing Spondylitis

NCT04947579
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
CC-99677, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
16
States / cities
Flagstaff, Arizona • Gilbert, Arizona • Phoenix, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 16, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo

NCT03097861
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
67
States / cities
Birmingham, Alabama • Foley, Alabama • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 16, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia

NCT00803023
View directory record Official record
Conditions
Fibromyalgia
Interventions
Sodium Oxybate, Sodium Oxybate & 6 Tablets, Sodium Oxybate & 8 Tablets, Sodium Oxybate Oral Solution (6 grams)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
32
States / cities
Phoenix, Arizona • Anaheim, California • Fair Oaks, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2011 · Synced Oct 16, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy and Safety Study of Iontophoretic Application of Terbinafine Gel in Subjects With Onychomycosis

NCT01080079
View directory record Official record
Conditions
Onychomycosis
Interventions
Terbinafine Hydrochloride, Purified Water
Drug · Other
Lead sponsor
Nitric BioTherapeutics, Inc
Industry
Eligibility
18 Years to 69 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
7
States / cities
Birmingham, Alabama • Sanford, Florida • Snellville, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2012 · Synced Oct 16, 2026, 10:45 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Efficacy of Extended-Release Liposomal Bupivacaine for Post-Operative Urogynecologic Surgery

NCT02287246
View directory record Official record
Conditions
Postoperative Pain
Interventions
Extended-Release liposomal bupivacaine (Exparel), Normal saline
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Oct 16, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes

NCT01475461
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Placebo, PF-04937319 - 3mg, PF-04937319 - 20mg, PF-04937319 - 50mg, PF-04937319 - 100mg, Sitagliptin - 100mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
24
States / cities
Anaheim, California • Los Angeles, California • Spring Valley, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 16, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)

NCT02398188
View directory record Official record
Conditions
Central Abdominal Bulging
Interventions
LIPO-202, Placebo
Drug
Lead sponsor
Evofem Inc.
Industry
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
35
States / cities
Birmingham, Alabama • Beverly Hills, California • Encinitas, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 16, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

NCT04470427
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30,415 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
100
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 16, 2026, 10:45 PM EDT
Recruiting Phase 2 Interventional

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

NCT07219459
View directory record Official record
Conditions
Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
Interventions
Visugromab RDE (recommended dose for expansion), Nivolumab, Lenvatinib, Placebo Saline Infusion
Biological · Drug · Other
Lead sponsor
CatalYm GmbH
Industry
Eligibility
18 Years to 100 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
6
States / cities
Irvine, California • Los Angeles, California • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 16, 2026, 10:45 PM EDT
Recruiting Phase 4 Interventional

Effect of Misoprostol on Fluid Deficit Volume in Hysteroscopic Myomectomy

NCT07286188
View directory record Official record
Conditions
Fibroids, Uterine, Fluid Deficit, Hysteroscopy / Methods
Interventions
Misoprostol Tabets, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 16, 2026, 10:45 PM EDT
Completed Not applicable Interventional

Predicting Analgesic Response to Acupuncture: A Practical Approach

NCT02890810
View directory record Official record
Conditions
Chronic Low Back Pain, Back Pain
Interventions
Real Acupuncture with Electrical Stimulation, Simulated Acupuncture with Electrical Stimulation
Other
Lead sponsor
Stanford University
Other
Eligibility
21 Years to 65 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 16, 2026, 10:45 PM EDT
Terminated Phase 2 Interventional Results available

A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA

NCT05462990
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
QUC398, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Tampa, Florida • Boston, Massachusetts • Morehead City, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 16, 2026, 10:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects

NCT06593457
View directory record Official record
Conditions
Healthy Volunteers
Interventions
IP, Matching Placebo
Drug
Lead sponsor
Nurix Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 16, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

NCT02007512
View directory record Official record
Conditions
Breast Cancer
Interventions
Enzalutamide, exemestane, Placebo (for enzalutamide)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
89
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Lakewood, Colorado + 54 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 16, 2026, 10:45 PM EDT
Completed Phase 4 Interventional Results available

Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)

NCT02519777
View directory record Official record
Conditions
HIV Infections
Interventions
Placebo for maraviroc (MVC), Placebo for dolutegravir (DTG), Dolutegravir (DTG), Maraviroc (MVC)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
23
States / cities
Los Angeles, California • San Diego, California • Torrance, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2022 · Synced Oct 16, 2026, 10:45 PM EDT
Terminated Phase 2 Interventional

Single Dose Enteral Tranexamic Acid in Critically Ill Patients

NCT01683747
View directory record Official record
Conditions
Shock, Sepsis, Hypotension, Critical Illness
Interventions
Tranexamic Acid, Control Intervention (Carrier fluid only)
Drug
Lead sponsor
San Diego Veterans Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 16, 2026, 10:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

To Study the Nutri-Genomic Response of Vit-D Supplementation in African-Americans

NCT02802449
View directory record Official record
Conditions
Hypovitaminosis D
Interventions
25 Hydroxy- Vitamin D3 [25 (OH) D3], Placebo
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 70 Years
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 16, 2026, 10:45 PM EDT